CRUK Cambridge Centre

  • Highly sensitive scanning technique used to monitor breast cancer
  • Targeting ‘normal’ cells in blood cancers could improve survival rates
  • Study identifies over 350 DNA 'errors' linked to breast cancer risk
  • Blocking survival mechanism to tackle melanoma treatment resistance
  • Cambridge to lead next generation radiotherapy research
  • Cambridge scientists receive funding boost to detect cancer earlier
  • Our Structure and Strategy - Beyond 2019
  • Clinical trial found my cancer and saved my life

The CRUK Cambridge Centre is a dynamic collaboration of researchers, clinicians, and the pharmaceutical and biotech industries based in the Cambridge area. We combine world-class science and technology with excellent patient care to pioneer new ways to prevent, detect and treat cancer.

By working together across different disciplines, we are breaking down the barriers between the laboratory and the clinic, enabling patients to benefit from the latest innovations in cancer science.

Patient care and clinical research
We offer a leading cancer care specialist service at Addenbrooke’s Hospital. We are committed to translating our clinical research to improve patient outcomes by recruiting the highest proportion of patients onto clinical trials in the UK.
Over 140 research groups work together across traditional academic, commercial and clinical boundaries. We connect cutting-edge science and technology from different disciplines to shed new light on preventing and controlling cancer.
Education and training
We educate and train the next generation of cancer scientists and clinicians. Working with the University of Cambridge we provide a stimulating learning environment for undergraduates, graduates, and postdoctoral researchers.

Subscribe to Centre News Latest news and events from CRUK Cambridge Centre

A fundamental change in our understanding of the childhood kidney cancer Wilms’ tumour is on the horizon, after the discovery of its earliest genetic root.
Cambridge scientists have received two out of seven new prostate cancer awards from the charity Prostate Cancer Research Centre (PCRC).
Whole genome sequencing of tumour cells could help predict the prognosis of a patient’s cancer and offer clues to identify the most effective treatment, suggests new study.